CBP-4888
Phase 1Small molecule
CBP-4888 is one of 39 small molecule programs targeting Preeclampsia. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
47 competitors in Preeclampsia
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Zofran
NovartisApproved
Cytotec
PfizerApproved
Innohep
Jazz PharmaceuticalsApproved
Levophed
GGeneral Hospital of Ningxia Medical University
Approved
Epsom Salt
FFresenius Kabi USA, LLC
Approved
Glucophage
EMD SeronoApproved
Cardene
Sun Pharmaceutical Industries, Inc.Approved
Aldactone
PfizerApproved
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CBP-4888. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CComanche Biopharma